Projects per year
Organisation profile
Organisation profile
The goal of the Infection and Immunotherapy Research (IIR) is to develop new immunotherapies against infectious diseases and cancer. They aim to provide a new translational understanding on HIV cure, bacterial infections and of cancer immunology. The group is also involved in clinical research working towards the elimination of HIV and Hepatitis in Luxembourg.
Aims and objectives
We focus on the development of immunotherapeutic complexes and NK cell engagers boosting innate immunity against viruses, bacteria and cancer cells for further elimination by the immune system. Our research encompasses protein engineering, virology, bacteriology, immunoassays and preclinical studies for the design of targeted therapeutic approaches.
HIV and viral hepatitis elimination
Our group support the monitoring of HIV and Hepatitis elimination in Luxembourg, as part of international research and surveillance networks, through outreach projects and clinical studies from the national HIV and Hepatitis programmes.
Fingerprint
Dive into the research topics where Infection and Immunotherapy Research is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
MICRO-PATH (Victoria Barros): Multimeric complexes to unlock the therapeutic potential of innate immunity against chronic respiratory infections
Seguin-Devaux, C. (PI) & Barros, V. (PhD Student)
FNR - Fonds National de la Recherche
1/10/25 → 30/09/29
Project: Research
-
PDAC-ORGA: Harnessing NK cells and Graphene Oxide Nanoparticles for Pancreatic Ductal Adenocarcinoma Immunotherapy
Seguin-Devaux, C. (PI)
1/09/25 → 30/11/29
Project: Research
-
PSEUDO: Pre-clinical validation of CoMiX and Bikes/Trikes against infections with Pseudomonas aeruginosa
Seguin-Devaux, C. (PI), Zimmer, J. (Partner), Si-Tahar, M. (Partner) & Pitiot, A. (Partner)
FNR - Fonds National de la Recherche
1/02/23 → 30/04/26
Project: Research
-
Directed-Complement Activation as a Novel Immunotherapeutic Approach for HER2-Breast Cancer
Seguin-Devaux, C., Brandus, B., Plesseria, J. M., Iserentant, G., Servais, J. Y., Pitiot, A., Kanli, G., Behrmann, I., Schober, R., Zimmer, J., Cohen, J. H. M. & Dervillez, X., 5 Sept 2025, In: ImmunoTargets and Therapy. 14, p. 979-995 17 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Directed-complement killing of Pseudomonas aeruginosa protects against lethal pneumonia
Pitiot, A., Brandus, B., Iserentant, G., Rolin, C., Servais, J. Y., Fouquenet, D., Chesnay, A., Richert, L., Briard, B., Si-Tahar, M., Mely, Y., Rassam, P., Zimmer, J., Desoubeaux, G., Dervillez, X. & Seguin-Devaux, C., Oct 2025, In: EBioMedicine. 120, 27 p., 105926.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Fighting Antibiotic Resistance: Insights Into Human Barriers and New Opportunities: Antibiotic Resistance Constantly Rises With the Development of Human Activities. We discuss Barriers and Opportunities to Get It Under Control
Pitiot, A., Rolin, C., Seguin-Devaux, C. & Zimmer, J., Jun 2025, In: BioEssays. 47, 6, e70001.Research output: Contribution to journal › Review article › peer-review
Open Access1 Citation (Scopus)